Elequin Capital’s TriSalus Life Sciences TLSI Stock Holding History

Elequin Capital’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,000	Closed	-$10K	–	726
2022 Q3	$10K	Buy	+1,000	New	+$9.89K	﹤0.01%	246

Other funds holding TLSI

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

DFCM

Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Elequin Capital's TLSI Position: Q4 2022 in Review

Elequin Capital sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 1,000 shares — an estimated $10K sold.

Elequin Capital first reported a position in TLSI in Q3 2022 and held it in 1 quarter. The position peaked at $10K in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

Elequin Capital reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
Elequin Capital sold 1,000 TriSalus Life Sciences shares in Q4 2022, an estimated $10K.
Elequin Capital first reported a position in TriSalus Life Sciences in Q3 2022 and held it in 1 quarter.
Elequin Capital's TriSalus Life Sciences position peaked at $10K in Q3 2022.
9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Elequin Capital's 13F filing for Q4 2022, filed 9 Feb 2023.